| Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with … LMS Boevé, MCCM Hulshof, AN Vis, AH Zwinderman, JWR Twisk, ... European urology 75 (3), 410-418, 2019 | 502 | 2019 |
| Prostate cancer detection at low prostate specific antigen FH Schröder, I Van Der Cruijsen-Koeter, HJ De Koning, AN Vis, ... The Journal of urology 163 (3), 806-812, 2000 | 468 | 2000 |
| Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome BWG Van Rhijn, AN Vis, TH Van Der Kwast, WJ Kirkels, F Radvanyi, ... Journal of clinical oncology 21 (10), 1912-1921, 2003 | 375 | 2003 |
| FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma BWG Van Rhijn, TH Van Der Kwast, AN Vis, WJ Kirkels, ER Boevé, ... Cancer research 64 (6), 1911-1914, 2004 | 283 | 2004 |
| Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non–muscle-invasive bladder cancer BWG Van Rhijn, TCM Zuiverloon, AN Vis, F Radvanyi, ... European urology 58 (3), 433-441, 2010 | 231 | 2010 |
| Prostate-specific antigen-based early detection of prostate cancer—validation of screening without rectal examination FH Schröder, M Roobol-Bouts, AN Vis, T van der Kwast, R Kranse Urology 57 (1), 83-90, 2001 | 177 | 2001 |
| The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer AN Vis, FH Schröder, TH van der Kwast European urology 50 (2), 258-265, 2006 | 172 | 2006 |
| Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Section Rotterdam: a comparison of two rounds of screening R Postma, FH Schröder, GJLH van Leenders, RF Hoedemaeker, AN Vis, ... European urology 52 (1), 89-97, 2007 | 153 | 2007 |
| Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles D Koppers-Lalic, M Hackenberg, R De Menezes, B Misovic, M Wachalska, ... Oncotarget 7 (16), 22566, 2016 | 140 | 2016 |
| Value of an immediate intravesical instillation of mitomycin C in patients with non–muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients J Bosschieter, JA Nieuwenhuijzen, T van Ginkel, AN Vis, B Witte, ... European urology 73 (2), 226-232, 2018 | 131 | 2018 |
| The FGFR3 mutation is related to favorable pT1 bladder cancer BWG Van Rhijn, TH Van Der Kwast, L Liu, NE Fleshner, PJ Bostrom, ... The Journal of urology 187 (1), 310-314, 2012 | 131 | 2012 |
| Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam IW Van Der Cruijsen-Koeter, AN Vis, MJ Roobol, MF Wildhagen, ... The Journal of urology 174 (1), 121-125, 2005 | 125 | 2005 |
| Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways AN Vis, FH Schröder BJU international 104 (4), 438-448, 2009 | 118 | 2009 |
| PROGNOSTIC VALUE OF CELL CYCLE PROTEINS p27kip1 AND MIB-1, AND THE CELL ADHESION PROTEIN CD44s IN SURGICALLY TREATED PATIENTS … AN VIS, MA NOORDZIJ, K FITOZ, MF WILDHAGEN, FH SCHRÖDER, ... The Journal of urology 164 (6), 2156-2161, 2000 | 115 | 2000 |
| Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer MCF Cysouw, BHE Jansen, T van de Brug, DE Oprea-Lager, E Pfaehler, ... European journal of nuclear medicine and molecular imaging 48, 340-349, 2021 | 105 | 2021 |
| Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy AN Vis, MO Boerma, S Ciatto, RF Hoedemaeker, FH Schröder, ... Urology 56 (4), 617-621, 2000 | 103 | 2000 |
| Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of … HB Luiting, PJ van Leeuwen, MB Busstra, T Brabander, HG van der Poel, ... BJU international 125 (2), 206-214, 2020 | 97 | 2020 |
| Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features JC Alers, PJ Krijtenburg, AN Vis, RF Hoedemaeker, MF Wildhagen, ... The American journal of pathology 158 (2), 399-406, 2001 | 91 | 2001 |
| Pathologic features of prostate cancer found at population-based screening with a four-year interval RF Hoedemaeker, TH van der Kwast, R Boer, HJ de Koning, M Roobol, ... Journal of the National Cancer Institute 93 (15), 1153-1158, 2001 | 83 | 2001 |
| A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy A Vis, A van der Gaast, B van Rhijn, T Catsburg, C Schmidt, G Mickisch Cancer chemotherapy and pharmacology 49, 342-345, 2002 | 78 | 2002 |
